Literature DB >> 6495243

Asbestos related pleuropulmonary lesions and the erythrocyte sedimentation rate.

G Hillerdal.   

Abstract

Asbestos related lesions of the lung parenchyma and the pleura can be divided into three main types: parietal pleural plaques, diffuse interstitial fibrosis ("classical asbestosis"), and a third type of reaction affecting both the pleura and the lung parenchyma. The last type includes such lesions as acute pleurisy, diffuse pleural thickening, and rounded atelectasis. Among 1344 patients with asbestos related pleural lesions, 1190 had pleural plaques, 29 of whom also had pulmonary fibrosis (asbestosis); 83 had unilateral sequelae of pleurisy, of whom nine had asbestosis; and 71 had bilateral sequelae of pleurisy, of whom 23 also suffered from asbestosis. The erythrocyte sedimentation rate (ESR) was measured in 184 patients--79 with pleural plaques, 44 with unilateral sequelae of pleurisy, and 61 with bilateral sequelae. In patients with pleural plaques with or without asbestosis the ESR was usually normal, the mean being 9.6 mm in one hour. Among patients with sequelae of pleurisy, however, many had a raised ESR. The mean ESR was 25.7 mm in one hour in those with bilateral changes and 13.2 in those with unilateral changes. Statistical analysis showed that in this group of subjects the presence of sequelae of pleurisy was a highly significant determining factor for the ESR (p less than 0.0001). Asbestosis alone was not a significant determining factor but there was a low grade of significance for the combined effect of asbestosis and sequelae of pleurisy (p less than 0.05). These findings suggest that the pathogenesis of the various changes is different.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6495243      PMCID: PMC459913          DOI: 10.1136/thx.39.10.752

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  16 in total

1.  Depression of viral interferon induction in cell monolayers by asbestos fibers.

Authors:  N Hahon; H L Eckert
Journal:  Environ Res       Date:  1976-02       Impact factor: 6.498

2.  Letter: T lymphocytes in abestosis.

Authors:  K Kang; Y Sera; T Okochi; Y Yamamura
Journal:  N Engl J Med       Date:  1974-10-03       Impact factor: 91.245

3.  Circulating rheumatoid and antinuclear factors in asbestos workers.

Authors:  M Turner-Warwick; W R Parkes
Journal:  Br Med J       Date:  1970-08-29

4.  [Round atelectasis (spherical and cylindrical atelectasis). Contribution to the differential diagnosis of intrapulmonal round foci].

Authors:  R Hanke
Journal:  Fortschr Geb Rontgenstr Nuklearmed       Date:  1971-02

5.  Changing attitudes to the diagnosis of asbestos disease.

Authors:  F A Mackenzie; P G Harries
Journal:  J R Nav Med Serv       Date:  1970

6.  Immunological studies of patients with asbestosis. II, Studies of circulating lymphoid cell numbers and humoral immunity.

Authors:  E Kagan; A Solomon; J C Cochrane; P Kuba; P H Rocks; I Webster
Journal:  Clin Exp Immunol       Date:  1977-05       Impact factor: 4.330

7.  An epidemiological survey of immunological abnormalities in asbestos workers. I. Nonorgan and organ-specific autoantibodies.

Authors:  A Lange
Journal:  Environ Res       Date:  1980-06       Impact factor: 6.498

8.  Sequential immunological studies in an asbestos-exposed population. II. Factors affecting lymphocyte function.

Authors:  M J Campbell; M M Wagner; M P Scott; D G Brown
Journal:  Clin Exp Immunol       Date:  1980-01       Impact factor: 4.330

9.  Asbestos exposure as a cause of immunological stimulation.

Authors:  M S Huuskonen; J A Räsänen; H Härkönen; S Asp
Journal:  Scand J Respir Dis       Date:  1978

10.  Pleural plaques in a health survey material. Frequency, development and exposure to asbestos.

Authors:  G Hillerdal
Journal:  Scand J Respir Dis       Date:  1978-10
View more
  1 in total

Review 1.  New developments in asbestos-related pleural disease.

Authors:  R M Rudd
Journal:  Thorax       Date:  1996-02       Impact factor: 9.139

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.